World Intravenous Immunoglobulin (IVIg) Industry

  • January 2015
  • -
  • Global Industry Analysts
  • -
  • 165 pages

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

Baxter International, Inc.
Beijing Tiantan Biological Products Co., Ltd.
Bharat Serums and Vaccines Limited
Biotest AG
China Biologic Products, Inc.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Intravenous Immunoglobulin - A Proliferating Biologic II-1
List of FDA-Approved and Off-Label Uses of Intravenous
Immunoglobulin Therapy II-2
Regional Market Perspective II-2
Table 1: Global Intravenous Immunoglobulin Market by
Geographic Region (2014): Percentage Share Breakdown of
Volume Sales for North America, Europe, Asia-Pacific
(incl.Japan), Latin America, and Rest of World (includes
corresponding Graph/Chart) II-3
Growth Drivers and Market Challenges II-3
Competitive Scenario II-4
Table 2: Global Intravenous Immunoglobulin Market by Leading
Player (2013): Percentage Market Share Breakdown of Value
Sales for Baxter, Biotest, CSL, Grifols, Kedrion, Non-Profit
Organizations, Octapharma, and Other Commercial Organizations
(includes corresponding Graph/Chart) II-4
IVIg Products Offered by Global Leading Players (2013) II-5

2. MARKET TRENDS II-6
Increasing Awareness of Primary Immunodeficiency Disease to
Drive IVIg Market II-6
Subcutaneous IG Formulations Gain Therapeutic Foothold II-6
Table 3: Global Subcutaneous Immunoglobulin Market: 2013-2020
(includes corresponding Graph/Chart) II-6

Table 4: Global SCIG Market by Leading Player (2014):
Percentage Market Share Breakdown of Revenue for Baxter, CSL,
and Grifols (includes corresponding Graph/Chart) II-7

Table 5: Global SCIG Sales for Primary Immunodeficiency
Disorders (PID) by Leading Player (2014): Percentage Market
Share Breakdown of Sales for Baxter, CSL, and Grifols
(includes corresponding Graph/Chart) II-7

Table 6: Global SCIG Sales for Chronic Inflammatory
Demyelinating Polyneuropathy by Leading Player: Percentage
Market Share Breakdown of Sales for Baxter, CSL, and Grifols
(2014) (includes corresponding Graph/Chart) II-7
Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead II-8
IVIg Treatment for Alzheimer’s Hindered by Unsuccessful
Clinical Trials II-8
Synthetic Replacements to IVIg Therapy II-9
IVIg Therapy - Home-based vs. Outpatient Settings II-9
IVIg Prices to Remain Strong both in the US and Outside the US II-9
Table 7: Average IVIg Product Price in the US during the
Years 2010-2014 (US$/gram) (includes corresponding
Graph/Chart) II-10
Per Capita Consumption Rate Varies Across Countries II-10
Table 8: Global Intravenous Immunoglobulin Market (2013): Per
Capita Consumption for Select Countries (in Kilograms per
Million Inhabitants) (includes corresponding Graph/Chart) II-10
Baxter’s Gammagard, the Leading Immunoglobulin Product in the US II-11
Strong Demand from Major Indications and Pipeline SCIg
Products to Fuel Growth II-11
Favorable Reimbursement and High Usage make US the Largest
Consumer of Immunoglobulins Worldwide II-12
Growing Adoption of Screening Programs to Reduce Usage of
Immunoglobulins in the Treatment of SCID II-12
Aging Global Population: Major Opportunity Indicator II-12
Table 9: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-13

Table 10: Life Expectancy at Age 60 and 80 Years -
(2010-2015), (2020-2025) and (2045-2050) (includes
corresponding Graph/Chart) II-14
Improving Healthcare Expenditure to Foster Growth II-14
Table 11: Top 20 Countries with the Highest Healthcare
Spending as a Percentage of GDP: 2012 (includes corresponding
Graph/Chart) II-15

3. PLASMA PROTEINS - AN OVERVIEW II-16
Plasma Market Witnesses Surging Demand II-16
Table 12: Global Plasma Market by Product (2013): Percentage
Share Breakdown of Sales for A1PI, Coagulation Factor IX,
Coagulation Factor VIII, Fibrinogen, Human Albumin, Ig for
Intramuscular Injection, IVIg, Prothrombin Complex, and
Specific Ig (includes corresponding Graph/Chart) II-16

Table 13: Global Market for Plasma Proteins by Geographic
Region (2013): Percentage Breakdown of Value Sales for
Asia-Pacific, Europe, Latin America, North America, and Rest
of World (includes corresponding Graph/Chart) II-17

Table 14: Global Plasma Products Market by Leading Player
(2013): Percentage Market Share Breakdown of Value Sales for
Baxter, Biotest, CSL, Grifols, Octapharma, and Others
(includes corresponding Graph/Chart) II-17
Regulations Exercise a Tight Rein over Plasma Therapy and
Immunoglobulins II-17

4. THERAPY OVERVIEW II-19
Immunoglobulins Overview II-19
Table 15: Global Immunoglobulin Usage by Indication (2013):
Percentage Share Breakdown of Volume Usage for Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP), Primary
Immunodeficiency Disorders (PID), Other Neuroimmunologic
Disorders, Immune Thrombocytopenic Purpura (ITP) and Others
(includes corresponding Graph/Chart) II-19

Table 16: Global Immunoglobulin (IVIg and SCIg) Market (2013):
Percentage Breakdown of Volume Share by Medical Specialty
(includes corresponding Graph/Chart) II-20
IVIg and SCIg: A Face-off! II-20
Cost of Product and Treatment II-20
Side-Effects II-20
Frequency of Treatment II-20
Safety Considerations II-21
Patient Response to Treatment Varies II-21
Site of Care II-21
IVIg Therapy Introduction II-21
Intravenous Immunoglobulin II-21
Mechanism of IVIg Action II-22
IVIg Dosage and Treatment Response Time II-23
Common IVIg Intravenous Dosing Recommendations by Indication II-23
Complications and Side Effects of Using IVIg II-23
Precautions to be Undertaken II-24
Intravenous Immunoglobulin - Indications II-24
FDA Approved Indications for IVIg II-24
Off-Label Usage of IVIg II-25
Select Off-Label Indications for IVIg II-25
Applications by Medical Specialty II-26
Neurology II-26
Hematology II-26
Immunology II-26
Dermatology II-26
Nephrology, Rheumatology, Ophthalmology, and Other Diseases II-26

5. REGULATORY APPROVALS II-27
CSL Behring Obtains EC Marketing Approval for Privigen® for
CIDP Patients II-27
CSL Behring Obtains FDA Approval for Privigen® to Treat PID
and ITP II-27
Biotest Pharmaceuticals Obtains FDA Approval for BIVGAMâ„¢ IVIg II-27
Baxter Obtains EC Marketing Approval for HyQvia II-27
Green Cross Receives Approval to Commence Phase III Clinical
Trials II-28
Baxter Bags FDA Approval for GAMMAGARD LIQUID to Treat MMN II-28

6. PRODUCT INNOVATIONS/INTRODUCTIONS II-29
Octapharma Canada Introduces Octagam®10% in Canada II-29
Biotest Introduces BIVIgAMâ„¢ in the US II-29

7. RECENT INDUSTRY ACTIVITY II-30
Emergent BioSolutions Acquires Cangene II-30
CMS Begins Evaluation of Payment for In-home IVIG Administration II-30
AxelaCare Acquires SCP Specialty Infusion II-30
Pfizer to License Gliknik’s GL-2045 II-30
Octapharma Completes Phase II Clinical Trial of Octagam 10%
for Alzheimer’s II-30
Grifols International Establishes New IVIg Purification
Facility in Los Angeles II-30
Sorrento Therapeutics Secures Global Rights for Using G-MAB®
Antibody Library Technology to Produce rIVIg II-31
Momenta Pharmaceuticals Acquires Sialic Switch Assets of
Virdante Pharmaceuticals II-31
Grifols’ AMBAR Study Integrates Therapeutic Plasmapheresis
with Alternating Infusion of IVIg and Albumin for Treatment
of Alzheimer’s Disease II-31
Biotest Publishes Clinical Trial Data Related to New
Investigational IVIg Product II-31

8. FOCUS ON SELECT PLAYERS II-32
Baxter International, Inc. (US) II-32
Beijing Tiantan Biological Products Co., Ltd (China) II-32
Bharat Serums and Vaccines Limited (India) II-32
Biotest AG (Germany) II-33
China Biologic Products, Inc (China) II-33
Guizhou Taibang Biological Products Co., Ltd (China) II-33
CSL Limited (Australia) II-34
CSL Behring LLC (US) II-34
Grifols, S.A (Spain) II-35
Hualan Biological Engineering Inc. (China) II-35
Kedrion S.p.A. (Italy) II-35
LFB Group (France) II-36
Octapharma AG (Switzerland) II-36
OMRIX Biopharmaceuticals Ltd (Israel) II-36
Shanghai RAAS Blood Products Co., Ltd. (China) II-37
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) II-37

9. GLOBAL MARKET PERSPECTIVE II-38
Value Analytics II-38
Table 17: World Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-38

Table 18: World Historic Review for Intravenous
Immunoglobulin by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-39

Table 19: World 15-Year Perspective for Intravenous
Immunoglobulin by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-40
Volume Analytics II-41
Table 20: World Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), and Rest of
World Markets Independently Analyzed with Annual Consumption
Volume in Kilograms for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-41

Table 21: World Historic Review for Intravenous
Immunoglobulin by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Consumption Volume
in Kilograms for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-42

Table 22: World 15-Year Perspective for Intravenous
Immunoglobulin by Geographic Region - Percentage Breakdown of
Volume Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-43


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Favorable Reimbursement and High Usage Make US the Largest
Consumer of Immunoglobulins Worldwide III-1
Table 23: The US Market for Intravenous Immunoglobulin by
Leading Player (2014): Percentage Market Share Breakdown of
Volume Sales for Baxter, CSL Behring, Grifols, Kedrion,
Octapharma, and Others (includes corresponding Graph/Chart) III-1

Table 24: The US Market for Immunoglobulins by Leading
Player (2014): Percentage Market Share Breakdown of Value
Sales for Gammagard Liquid/Kiovig, Flebogamma/ Gamunex,
Privigen/Carimune NF, Octagam and Others (includes
corresponding Graph/Chart) III-2

Table 25: The US Market for IVIg Products by Indication
(2014 and 2020E): Percentage Breakdown of Volume Sales for
CIDP, CLL, ITP, MMN, PID, and Other Neurological Diseases
(includes corresponding Graph/Chart) III-2
Ageing Demographics: A Key Market Driver III-3
Table 26: North American Elderly Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-3
Intravenous Immunoglobulin Reimbursement Scenario III-3
US Market Pricing Analysis III-4
Table 27: The US IVIg Pricing by Company and Brand (US$/g):
Comparative Analysis of Pricing for 2012, 2013, and 2014
(includes corresponding Graph/Chart) III-4
Growing Adoption of Screening Programs to Reduce Usage of
Immunoglobulins in the Treatment of SCID III-5
US Blood Supply System - A Schematic III-5
Regulatory Approvals III-6
Product Launch III-7
Strategic Corporate Developments III-7
Select Major Players III-8
B.Market Analytics III-10
Value Analytics III-10
Table 28: The US Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-10

Table 29: The US Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-11
Volume Analytics III-12
Table 30: The US Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Consumption Volume
in Kilograms for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-12

Table 31: The US Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-13

2. CANADA III-14
A.Market Analysis III-14
Highest Per Capita Consumption of Intravenous Immunoglobulin III-14
Canadian Blood Services - At the Forefront of Blood
Collection in Canada III-14
Product Launch III-14
B.Market Analytics III-15
Value Analytics III-15
Table 32: Canadian Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-15

Table 33: Canadian Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-16
Volume Analytics III-17
Table 34: Canadian Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Consumption
Volume in Kilograms for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-17

Table 35: Canadian Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-18

3. JAPAN III-19
A.Market Analysis III-19
Graying Population to Drive Market Growth III-19
Table 36: Japanese Elderly (65+ Years) Population:
2000-2020 (includes corresponding Graph/Chart) III-19
B.Market Analytics III-20
Value Analytics III-20
Table 37: Japanese Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-20

Table 38: Japanese Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-21
Volume Analytics III-22
Table 39: Japanese Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Consumption
Volume in Kilograms for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-22

Table 40: Japanese Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-23

4. EUROPE III-24
A.Market Analysis III-24
Outlook III-24
Ageing Population Drives Demand III-24
Table 41: European Country-wise Statistics of 60+
Population as % of Total Population: 2013 (includes
corresponding Graph/Chart) III-25
Key Statistics III-26
Table 42: European Market for Intravenous Immunoglobulin by
Leading Player (2014): Percentage Market Share Breakdown of
Volume Sales by Plasma Fractionators for Baxter Healthcare,
Biotest, CSL Behring, Grifols, Kedrion, Octapharma, and
Others (includes corresponding Graph/Chart) III-26

Table 43: European Immunoglobulin (IVIg and SCIg) Per
Capita Consumption in Kilograms per Million Inhabitants
(2012) (includes corresponding Graph/Chart) III-26
European Sub-Q IVIg Product Approvals III-26
Regulatory Approvals III-27
B.Market Analytics III-28
Value Analytics III-28
Table 44: European Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin by Geographic Region -
France, Germany, Italy, UK, Spain and Rest of Europe
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-28

Table 45: European Historic Review for Intravenous
Immunoglobulin by Geographic Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2012 (includes corresponding
Graph/Chart) III-29

Table 46: European 15-Year Perspective for Intravenous
Immunoglobulin by Geographic Region - Percentage Breakdown
of Revenues for France, Germany, Italy, UK, Spain and Rest
of Europe Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-30
Volume Analytics III-31
Table 47: European Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Consumption
Volume in Kilograms for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-31

Table 48: European Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-32

4a. FRANCE III-33
A.Market Analysis III-33
Research Initiative in France III-33
High-dose Intravenous Immunoglobulin to Offer Respite for
Primary Sjögren’s Syndrome Patients III-33
LFB Group - A Key Player III-33
B.Market Analytics III-34
Table 49: French Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-34

Table 50: French Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-35

4b. GERMANY III-36
A.Market Analysis III-36
Biotest AG - A Key Player III-36
B.Market Analytics III-37
Table 51: German Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-37

Table 52: German Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-38

4c. ITALY III-39
A.Market Analysis III-39
Kedrion S.p.A. - A Key Player III-39
B.Market Analytics III-39
Table 53: Italian Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-39

Table 54: Italian Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-40

4d. THE UNITED KINGDOM III-41
A.Market Analysis III-41
New Concept to Stimulate Plasma Market: Welsh lood Service
Proposes Sale of Blood Plasma III-41
B.Market Analytics III-42
Table 55: The UK Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-42

Table 56: The UK Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-43

4e. SPAIN III-44
A.Market Analysis III-44
Strategic Corporate Development III-44
Grifols, S.A - A Key Player III-44
B.Market Analytics III-45
Table 57: Spanish Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-45

Table 58: Spanish Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-46

4f. REST OF EUROPE III-47
A.Market Analysis III-47
Strategic Corporate Development III-47
Octapharma AG (Switzerland) - A Key Player III-47
B.Market Analytics III-48
Table 59: Rest of European Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-48

Table 60: Rest of European Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-49

5. ASIA-PACIFIC III-50
A.Market Analysis III-50
Table 61: Asia-Pacific Market for Immunoglobulin (IVIg and
SCIg) (2012): Per Capita Consumption (in Kilograms per
Million Inhabitants) (includes corresponding Graph/Chart) III-50
B.Market Analytics III-51
Value Analytics III-51
Table 62: Asia-Pacific Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin by Geographic
Region - Australia, China and Rest of Asia-Pacific Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-51

Table 63: Asia-Pacific Historic Review for Intravenous
Immunoglobulin by Geographic Region - Australia, China and
Rest of Asia-Pacific Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) III-52

Table 64: Asia-Pacific 15-Year Perspective for Intravenous
Immunoglobulin by Geographic Region - Percentage Breakdown
of Revenues for Australia, China and Rest of Asia-Pacific
Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-53
Volume Analytics III-54
Table 65: Asia-Pacific Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin with Annual
Consumption Volume in Kilograms for Years 2013 through 2020
(includes corresponding Graph/Chart) III-54

Table 66: Asia-Pacific Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-55

5a. AUSTRALIA III-56
A.Market Analysis III-56
Overview III-56
Table 67: Australian IVIg Usage by Main Indications (% of
grams used annually) (includes corresponding Graph/Chart) III-56
Revised Criteria for Clinical Use of IVIg in Australia III-57
Australian Blood Products Market - An Overview III-57
Australian Red Cross Blood Service III-57
CSL Limited - A Key Player III-58
B.Market Analytics III-58
Table 68: Australian Recent Past, Current and Future Analysis
for Intravenous Immunoglobulin with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-58

Table 69: Australian Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-59

5b. CHINA III-60
A.Market Analysis III-60
Unmet Plasma Protein Needs Presents Opportunities III-60
Table 70: IVIg Annual Supply in China: 2010- 2013 (includes
corresponding Graph/Chart) III-60

Table 71: Chinese Market for IVIg Products by Major Player
(2013): Percentage Market Share Breakdown of Value Sales
for Chengdu, CBPO, Hualan Biological, Shanghai Institute of
Biological Products, Shanxi Kangbao, Sichuan Yuanda
Shuyang, and Others (includes corresponding Graph/Chart) III-61
Select Key Players III-61
B.Market Analytics III-64
Table 72: Chinese Recent Past, Current and Future Analysis for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-64

Table 73: Chinese Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-65

5c. REST OF ASIA-PACIFIC III-66
A.Market Analysis III-66
Outlook III-66
Indonesia - An Overview III-66
Bharat Serums and Vaccines Ltd (India) - A Key Player III-66
B.Market Analytics III-67
Table 74: Rest of Asia-Pacific Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-67

Table 75: Rest of Asia-Pacific Historic Review for
Intravenous Immunoglobulin with Annual Revenue Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-68

6. REST OF WORLD III-69
A.Market Analysis III-69
Overview of the Middle East III-69
Iran Attains Self-Sufficiency in Plasma Production III-69
OMRIX Biopharmaceuticals Ltd (Israel) - A Key Player III-69
B.Market Analytics III-70
Value Analytics III-70
Table 76: Rest of World Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin with Annual Revenue
Figures in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) III-70

Table 77: Rest of World Historic Review for Intravenous
Immunoglobulin with Annual Revenue Figures in US$ Million
for Years 2006 through 2012(includes corresponding
Graph/Chart) III-71
Volume Analytics III-72
Table 78: Rest of World Recent Past, Current and Future
Analysis for Intravenous Immunoglobulin with Annual
Consumption Volume in Kilograms for Years 2013 through 2020
(includes corresponding Graph/Chart) III-72

Table 79: Rest of World Historic Review for Intravenous
Immunoglobulin with Annual Consumption Volume in Kilograms
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-73


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 25 (including Divisions/Subsidiaries - 30)

The United States (10)
Japan (1)
Europe (7)
- France (1)
- Germany (1)
- The United Kingdom (1)
- Italy (1)
- Spain (1)
- Rest of Europe (2)
Asia-Pacific (Excluding Japan) (10)
Latin America (1)
Middle East (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Markets for Drug-Device Combinations

Global Markets for Drug-Device Combinations

  • $ 6 650
  • Industry report
  • January 2015
  • by BCC Research

REPORT HIGHLIGHTS The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth ...

Blood & Organ Bank Lines World Report

Blood & Organ Bank Lines World Report

  • $ 4 609
  • Industry report
  • February 2015
  • by PureData

BLOOD & ORGAN BANK LINES WORLD REPORT The Blood & Organ Bank Lines World Report gives Market Consumption / Products / Services for over 200 countries by 6 to 10-Digit NAICS Product Codes by 3 Time series: ...

2014 Market Research Report on Global Coagulant Production Industry

2014 Market Research Report on Global Coagulant Production Industry

  • $ 3 600
  • Industry report
  • December 2014
  • by QY Research Group

Summary 2014 Market Research Report on Global Coagulant Production Industry is a professional and depth research report on Global Coagulant Production industry For overview analysis, the report introduces ...

Blood & Organ Bank Lines Asia Report

February 2015 $ 2 969

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.